

## Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19

Mao, Ren; Qiu, Yun; He, Jin-Shen; Tan, Jin-Yu; Li, Xue-Hua; Liang, Jie; Shen, Jun; Zhu, Liang-Ru; Chen, Yan; Iacucci, Marietta; Ng, Siew C; Ghosh, Subrata; Chen, Min-Hu

DOI:

[10.1016/S2468-1253\(20\)30126-6](https://doi.org/10.1016/S2468-1253(20)30126-6)

License:

Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

*Document Version*

Peer reviewed version

*Citation for published version (Harvard):*

Mao, R, Qiu, Y, He, J-S, Tan, J-Y, Li, X-H, Liang, J, Shen, J, Zhu, L-R, Chen, Y, Iacucci, M, Ng, SC, Ghosh, S & Chen, M-H 2020, 'Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis', *The Lancet Gastroenterology and Hepatology*, vol. 5, no. 7, pp. 667-678. [https://doi.org/10.1016/S2468-1253\(20\)30126-6](https://doi.org/10.1016/S2468-1253(20)30126-6)

[Link to publication on Research at Birmingham portal](#)

### General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

### Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

1 **Manifestations and Prognosis of Gastrointestinal and Liver Involvement in**  
2 **Patients with COVID-19: a Rapid Systematic Review and Meta-analysis**

3

4 **Short Title: Gastrointestinal and Liver Involvement in COVID-19**

5

6 Ren Mao, MD<sup>1\*</sup>, Yun Qiu, MD<sup>1\*</sup>, Jin-Shen He, MD<sup>1\*</sup>, Jin-Yu Tan, MD<sup>1\*</sup>, Xue-Hua  
7 Li, MD<sup>2\*</sup>, Prof. Jie Liang, MD<sup>3</sup>, Jun Shen, MD<sup>4</sup>, Prof. Liang-Ru Zhu, MD<sup>5</sup>, Prof.  
8 Yan Chen, MD<sup>6</sup>, Marietta Iacucci, MD<sup>7</sup>, Prof. Siew C Ng, MD<sup>8</sup>, Prof. Subrata Ghosh,  
9 MD<sup>7</sup>, and Prof. Min-Hu Chen, MD<sup>1</sup>

10

11 \*These authors contributed equally.

12

13 <sup>1</sup>Department of Gastroenterology, The First Affiliated Hospital of Sun Yat-sen  
14 University, 58 Zhongshan II Road, Guangzhou, 510080, People's Republic of China.

15 <sup>2</sup>Department of Radiology, The First Affiliated Hospital of Sun Yat-sen University, 58  
16 Zhongshan II Road, Guangzhou, 510080, People's Republic of China.

17 <sup>3</sup>State key Laboratory of Cancer Biology, National Clinical Research Center for  
18 Digestive Diseases and Xijing Hospital of Digestive Diseases, Air Force Medical  
19 University, Xi'an, 710032, People's Republic of China.

20 <sup>4</sup>Division of Gastroenterology and Hepatology, Ren Ji Hospital, School of Medicine,  
21 Shanghai Jiao Tong University, Shanghai Cancer Institute, Shanghai Institute of

1 Digestive Disease, Shanghai Inflammatory Bowel Disease Research Center, Shanghai,  
2 160 Pu Jian Ave, Shanghai 200127, People's Republic of China.

3 <sup>5</sup>Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong  
4 University of Science and Technology, Wuhan, People's Republic of China.

5 <sup>6</sup>Yan Chen , Center for Inflammatory Bowel Diseases, Department of Gastroenterology,  
6 the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou  
7 310009, China.

8 <sup>7</sup>NIHR Biomedical Research Institute, Institute of Translational Medicine, University  
9 of Birmingham and University Hospitals Birmingham NHS Foundation Trust, United  
10 Kingdom.

11 <sup>8</sup>Department of Medicine and Therapeutics, The Chinese University of Hong Kong,  
12 New Territories, Hong Kong. Institute of Digestive Disease, State Key Laboratory of  
13 Digestive Diseases, LKS Institute of Health Science, The Chinese University of Hong  
14 Kong, New Territories, Hong Kong

15

16 **Corresponding author:**

17 Prof. Min-Hu Chen and Prof. Ren Mao, Department of Gastroenterology, The First  
18 Affiliated Hospital of Sun Yat-sen University, 58 Zhongshan II Road, Guangzhou,  
19 510080, People's Republic of China (e-mail: chenminhu@mail.sysu.edu.cn;  
20 maoren2023@gmail.com).

21

1 **Conflict of interest :**

2 All authors declared no conflict of interest

3 **Grant support:** None

4

5 **Author contributions:**

6 R Mao and MH Chen conceived the study. S Ghosh, MH Chen, S Ng supervised the  
7 overall study. R Mao and Y Qiu wrote the manuscript. R Mao, Y Qiu, JS He, JY Tan  
8 and XH Li analyzed the data. J Shen, J Liang, LR Zhu, Y Chen and M Iacucci critically  
9 revised the manuscript.

10

11 **Research in context**

12 **Evidence before this study**

13 The emergence and spread of COVID-19 has brought great challenges to global public  
14 health. There are increasing number of studies reporting the gastrointestinal (GI)  
15 symptom and liver injury in patients with COVID-19, and severe patients tend to have  
16 a higher risk of developing GI symptoms and abnormal liver function. However, results  
17 were inconsistent with remarkable heterogeneity among studies and the exact  
18 magnitude of GI and liver involvement remains uncertain. Study providing detailed  
19 pooled estimates of incidence of gastrointestinal and liver involvement in COVID-19  
20 is needed. Whether this unique group of patients has a poor disease course remains  
21 unclarified.

1 **Added value of this study**

2 We searched the PubMed, Embase, Web of Science, WHO database of publications,  
3 the Lancet COVID-19 Resource Centre, NEJM, JAMA, BMJ, Gastroenterology, GUT,  
4 American Journal of Gastroenterology, and Centers for Disease Control and Prevention  
5 (CDC) COVID-19 publications. We present pooled estimate rate of GI symptom and  
6 liver injury in COVID-19. Furthermore, we present the subgroup analysis of severe vs  
7 non-severe cases, patients in Hubei province vs outside Hubei, and paediatric vs adult  
8 patients. Features of patients with pre-existing digestive diseases and initially  
9 presenting with GI symptoms were summarized. The disease course of patients with  
10 digestive system involvement was further analysed.

11

12 **Implications of all the available evidence**

13 Digestive symptom and liver injury are not uncommon in patients with COVID-19.  
14 Compared with non-severe cases, severe cases with COVID-19 had a higher risk of  
15 developing GI symptoms and liver injury. Paediatric patients have equivalent  
16 prevalence of presenting with GI symptoms compared to adult patients. Patients in  
17 Hubei had higher rate of abnormal liver functions compared to those outside Hubei.  
18 One tenth of patients with COVID-19 may present only with GI symptoms without  
19 respiratory symptoms. Patients with digestive system involvement have delayed  
20 diagnosis with a tendency to progress to severe/critical type and a poor disease course.

21

1 **Summary**

2 **BACKGROUND:** The prevalence and prognosis of digestive system involvement  
3 including gastrointestinal symptoms and liver injury in patients with COVID-19  
4 remains largely underappreciated. Here we performed a meta-analysis to quantify the  
5 effects of COVID-19 on digestive system.

6 **METHODS:** We systematically searched databases for studies reporting digestive  
7 system symptoms in COVID-19 patients up to April 4, 2020. Raw data from studies  
8 were pooled to determine effect estimates.

9 **FINDINGS:** We analyzed findings from 35 studies including 6,686 COVID-19  
10 patients that met inclusion criteria. The pooled estimate of digestive system  
11 comorbidities rate was 4% (95% CI: 2%- 5%; range: 0%–15%;  $I^2=74%$ ). The pooled  
12 rate of digestive symptoms was 15% (95% CI: 10%- 21%; range: 2%–57%;  $I^2= 96%$ )  
13 with nausea and/or vomiting, diarrhoea and loss of appetite being the three most  
14 common ones. The pooled estimate of abnormal liver functions was 19% (95% CI: 9%-  
15 32%; range: 1%-53%;  $I^2= 96%$ ). Subgroup analysis showed patients with severe cases  
16 had higher rate of GI symptoms (OR1.61, 95% CI: 1.26-2.06,  $p=0.0040$ ,  $I^2=35%$ ) and  
17 liver injury (OR 2.2, 95% CI: 1.60-3.02,  $p<0.001$ ,  $I^2=36%$ ,) compared to non-severe  
18 cases. Patients in Hubei province where the COVID-19 initial outbreak happened in  
19 China are more likely to present with abnormal liver functions (all  $< 0.01$ ) compared  
20 with those outside Hubei. Paediatric patients have similar prevalence of GI symptoms  
21 compared to adult patients. About 10% (95% CI: 4%- 19%; range: 3%–23%;  $I^2= 97%$ )

1 patients presented with GI symptoms alone without respiratory features. Patients with  
2 GI system involvement tend to have delayed diagnosis (SMD 2.85, 95% CI: 0.22-5.48,  
3  $p=0.030$ ,  $I^2=73\%$ ) and poor disease course.

4

5 **INTERPRETATIONS:** Our study showed that digestive symptom and liver injury are  
6 not uncommon in patients with COVID-19. Compared with non-severe cases, severe  
7 cases with COVID-19 had a higher risk of developing GI symptoms and liver injury.

8 Paediatric patients with COVID-19 have equivalent risk of GI symptoms compared  
9 with adult patients. One tenth of patients with COVID-19 may present only with GI

10 symptoms without respiratory symptoms. Patients with digestive system involvement  
11 have delayed diagnosis with a tendency to have a poor disease course.

12

13 **FUNDINGS:** None

14

## 1 **Introduction**

2 The outbreak of coronavirus disease 2019 (COVID-19) has been tremendously  
3 impacting the entire world since December 2019. As of April 3rd, 2020, more than 900  
4 000 laboratory-confirmed cases and more than 50 000 deaths in over 100 countries had  
5 been reported.<sup>1</sup>

6 Respiratory tract manifestations such as fever and cough are the most common reported  
7 symptoms in patients with COVID-19.<sup>2</sup> The evidence of digestive system involvement  
8 in COVID-19 was first reported by a group in China.<sup>3</sup> Emerging data showed that the  
9 gastrointestinal (GI) tract and liver might also represent target organs of Severe Acute  
10 Respiratory Syndrome Corona Virus 2 (SARS-CoV-2), based on the findings that cell  
11 receptor angiotensin converting enzyme II (ACE2), the major receptor of SARS-CoV-  
12 2, is expressed in GI tract as well as liver cells.<sup>4</sup> More importantly, the evidence of  
13 SARS-CoV-2 detection in patients' stool and the potential faecal-oral route transmission  
14 have raised great concern and posed a challenge for control and prevention of COVID-  
15 19.<sup>5-7</sup>

16 There are increasing number of studies reporting the GI symptom and liver injury in  
17 patients with COVID-19, and severe patients tend to have a higher risk of developing  
18 GI symptoms and abnormal liver function.<sup>2</sup> However, results were inconsistent with  
19 remarkable heterogeneity among studies and the exact magnitude of GI and liver  
20 involvement remains uncertain. Compared to adult patients, paediatric patients seem to



1 have clinically milder symptoms and showed less alterations in radiological and  
2 laboratory testing parameters.<sup>8</sup> Whether paediatric patients had lower risk of GI and liver  
3 involvement remains unclear. Moreover, several studies have provided information on  
4 the epidemiology and clinical manifestation of the disease outside Hubei province.  
5 Whether the GI manifestation and liver injury in disease in Hubei differs from that  
6 outside Hubei has seldom been evaluated.<sup>9, 10</sup>  
7 More importantly, the prognosis of COVID-19 patients with GI symptoms is still largely  
8 unknown. Recent studies<sup>11, 12</sup> implied that COVID-19 patients with digestive symptoms  
9 may have a worse clinical outcome compared to those without digestive symptoms,  
10 emphasizing the importance of including symptoms such as diarrhoea to diagnose  
11 COVID-19 early. As demonstrated by a recent study, the rate of the severe/critical type  
12 was also markedly increased in COVID-19 patients with GI symptoms than in those  
13 without GI symptoms. Moreover, COVID-19 patients with GI symptoms had  
14 significantly higher complications of acute respiratory distress syndrome (ARDS) and  
15 liver injury than those without these symptoms.<sup>11</sup> Pan et al<sup>12</sup> also showed that as the  
16 severity of the disease increased, digestive symptoms became more pronounced.  
17 We performed a systematic review and meta-analysis of current emerging studies  
18 reporting GI symptoms and liver injury in patients with COVID-19 based on different  
19 disease severity, age groups and geographical regions. We also explored the disease  
20 course of this subgroup of patients with GI symptoms. We aimed to update the  
21 information with high evidence level and provide insights into the epidemiology of

1 digestive system involvement in COVID-19 as an urgent issue in presentation of  
2 COVID-19.

3

#### 4 **Materials and Methods**

5 The study was performed following the Preferred Reporting Items for Systematic  
6 reviews and Meta-Analyses guidelines (The PRISMA Statement ) (**Supplementary**  
7 **material**).

8

#### 9 **Search strategy and selection criteria**

##### 10 *Literature Search*

11 A systematic literature search of PubMed, Embase (Elsevier) and Web of Science  
12 databases was performed on April 4th, 2020 (updated April 10th, 2020), using the  
13 keywords “coronavirus,” “severe acute respiratory syndrome coronavirus 2”, “SARS-  
14 CoV-2”, “novel coronavirus”, “nCoV,” “2019-nCoV,” and “COVID-19.” Considering  
15 the urgency of the topic and the need to increase the sensitivity of the search, a gray  
16 literature search was performed using the same keywords on Google Scholar to capture  
17 the most recently published articles. Furthermore, the World Health  
18 Organization(WHO) database of publications, the Lancet COVID-19 Resource Centre,  
19 NEJM, JAMA, BMJ, Gastroenterology, GUT, American Journal of Gastroenterology  
20 and Centers for Disease Control and Prevention (CDC) COVID-19 publications were  
21 screened for potentially relevant publications. Additional articles were retrieved by

1 screening the reference lists of included studies and from the archives of the reviewers.  
2 Literature search was restricted to English language. One of the reviewers (YQ) with  
3 experience in database searches designed the search strategy, which was subsequently  
4 revised by other reviewers. In consideration of the date of the earliest confirmed reports  
5 of COVID-19, the search was limited to 2020 with the start date of January 1st 2020.  
6 Because of the large number of records identified from the gray literature, the Google  
7 Scholar search was limited to titles. However, no additional limits were applied in the  
8 PubMed, Embase or Web of Science search. Records were managed by EndNote X 9.0  
9 software to exclude duplicates.

10

### 11 *Eligibility Criteria and Study Selection*

12 Eligible studies reported the epidemiological, clinical features of COVID-19, and the  
13 prevalence of GI findings in infected patients. Literature were included with restriction  
14 to English language. Given that pre-print papers in database such as bioRxiv and  
15 medRxiv were not peer-reviewed, we did not include the publications in our present  
16 analysis to avoid any potential misinformation being disseminated at present. The  
17 following studies were excluded: (a) duplicate publications, (b) reviews, editorials, (c)  
18 single case report and (d) studies pertaining to other coronavirus-related illnesses, such  
19 as Middle East respiratory syndrome (MERS), and (d) small case series (<10 cases).  
20 Two reviewers (YQ, JSH) independently screened the titles and abstracts according to

1 these eligibility criteria. Disagreement was discussed with other reviewers and  
2 subsequently resolved via consensus.

3

#### 4 ***Risk of Bias***

5 Two reviewers (JSH, JYT) independently rated the quality of included studies using  
6 the National Institutes of Health Quality Assessment Tool for Case Series Studies<sup>13</sup>.

7 Any disagreement was resolved by the third senior reviewer (RM).

8

#### 9 **Data extraction and definitions**

10 The two investigators (QY and JSH) who performed the literature search also  
11 independently extracted the data from included studies. Disagreements were resolved  
12 by a third investigator (RM) or by consensus. We extracted the following variables:  
13 author, date, study design, country, patient demographics, number of participates in  
14 severe and non-severe disease group, the prevalence of clinical GI symptoms such as  
15 vomiting, nausea, diarrhoea, loss of appetite, abdominal pain, and belching, together  
16 with digestive system comorbidities including liver disease, and gastrointestinal  
17 diseases. Liver injury was defined according to the studies. Any kind of abnormal of  
18 liver damage indices such as Alanine aminotransferase (ALT), Aspartate  
19 aminotransferase (AST), and total bilirubin (TB) was also classified as liver injury. The  
20 disease severity was defined according to the studies, mainly based on the symptoms  
21 present at diagnosis, in some cases, patients with pulse oxygen saturation

1 (SpO<sub>2</sub>)<90%<sup>14</sup> or need of intensive care unit (ICU) care<sup>15</sup> or with ARDS<sup>16</sup> were also  
2 classified as severe cases. COVID-19 was diagnosed on the basis of the WHO interim  
3 guidance.<sup>17</sup>

4  
5 **Data Synthesis and Statistical Analysis**

6 For estimate of standardised mean difference (SMD) or weighted mean differences, we  
7 used 2 simple formulas proposed by Hozo et al<sup>18</sup> to estimate the mean using the values  
8 of the median, the low and high ends of the range, and the sample size. The odds ratio  
9 (OR, 95% confidence intervals (CI)) was used to describe the ratio of the probability of  
10 events occurring in severe vs. non-severe patients with COVID-19. Owing to  
11 heterogeneity within and between studies, a random effect model was used to estimate  
12 the average effect and its precision, which would give a more conservative estimate of  
13 the 95% CI. We used the  $I^2$  statistic and Cochran's Q test to assess statistical  
14 heterogeneity. A meta-analysis was planned to assess the association of GI symptoms  
15 and liver injury with demographic data, outcomes, and disease characteristics. The  
16 meta-analysis was performed using the metaprop command of the meta package in R  
17 (version 3.2.0) for pooling single-armed rates, Stata (version 12.1) with the commands  
18 metareg (for meta-regression) for assessment of publication bias, and Review Manager  
19 (RevMan version 5.3, Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration,  
20 2014) for all the other analyses.

21 **Publication Bias**

1 Funnel-plot asymmetry as proposed by Begg and Egger et al<sup>19</sup> was used to investigate  
2 the possibility of publication bias.

3

4 **Role of the funding source**

5 There is no funding for this study. The corresponding author had full access to all the  
6 data in the study and had final responsibility for the decision to submit for publication.

7

8

# 1 RESULTS

## 2 1.Study selection

3 Among the 8,948 records that were identified through electronic and hand-search  
4 strategies after removal of duplication, two reviewers (YQ and JSH) independently  
5 evaluated the titles and abstracts, removed 8,896 irrelevant studies, and selected 52  
6 potentially relevant reports that were identified and retrieved for detailed evaluation.

7 Two studies<sup>20, 21</sup> were excluded due to lack of absolute numbers for outcomes, 8  
8 studies<sup>22-29</sup> were excluded due to case series with patients <10, and 7 studies were  
9 further excluded due to being pre-print papers in database medRxiv, thus 35 studies<sup>2, 8,  
10 9, 12, 14-16, 30-57</sup>, comprising 6,686 patients with COVID-19 met the inclusion criteria and  
11 were included in the quantitative synthesis (**Figure 1**).

12

## 13 2. Characteristics and assessment of quality of the included studies

14 The main characteristics of patients and studies included in the meta-analysis are shown  
15 in (**Appendix, Supplementary Table 1**). The majority of studies were from China,  
16 except one from Singapore<sup>31</sup> and one from United States.<sup>30</sup> The studies included mainly  
17 adult patients except four paediatric studies<sup>8, 37, 43, 54</sup> and 6 studies<sup>2, 9, 38, 45, 46, 53</sup> with  
18 small group of paediatric patients (36 patients in total). All the included studies were  
19 rated low by National Institutes of Health (NIH) Quality Assessment Tool for Case  
20 Series Studies (**Appendix, Supplementary Table 2**).

21

1 **3. Gastrointestinal features**

2 **3.1 Digestive system comorbidities**

3 By combining 21 studies reporting GI data of patients with COVID-19 at diagnosis, the  
4 pooled estimate of digestive system comorbidities (i.e underlying gastrointestinal  
5 disease and liver disease) rate was 4% (95% CI: 2%- 5%; range: 0–15%;  $I^2=74%$ ;  
6 **supplementary. Figure 1**). Specifically, the pooled estimate rate of liver disease  
7 comorbidities was 3% (95% CI: 2%–4%; range: 0– 25%;  $I^2=57%$ ). The most reported  
8 digestive system comorbidities included chronic hepatitis or liver cirrhosis, and peptic  
9 ulcer.

10

11 **3.2 Gastrointestinal symptoms as the initial presenting symptoms**

12 Gastrointestinal symptoms as the initial symptoms have been reported in several case  
13 series.<sup>40</sup> COVID-19 induced diarrhoea at onset was first reported in a patient with  
14 COVID-19,<sup>58</sup> and subsequently confirmed by cases in Singapore<sup>31</sup> and Japan<sup>59</sup>.

15 The pooled estimate of GI symptoms as presenting symptoms was 10% (95% CI: 4%-  
16 19%; range: 3%–23%;  $I^2= 97%$ ; 5 studies, **supplementary Figure 2**). Patients  
17 presenting with GI symptoms had longer duration from illness onset to admission  
18 (SMD 2.85, 95% CI: 0.22-5.48,  $p=0.030$ ,  $I^2=73%$ ).

19 The result regarding detection of COVID-19 virus Ribonucleic Acid (RNA) in stool or  
20 rectal swab is summarized in **Appendix, Supplementary Table 3**.<sup>5, 8, 31, 37, 59-64</sup> The



1 positivity rate of COVID-19 viral RNA in faecal samples was 54% (95% CI 44%-64%,  
2  $I^2=28\%$ ).

3

### 4 **3.3 Rate of gastrointestinal symptoms**

5 GI symptoms and abnormal liver function in patients with COVID-19 from the included  
6 studies are summarized in **Appendix, Supplementary Table 4**. Combining all 29  
7 studies (n=6,064) reporting GI symptoms in patients with COVID-19 at diagnosis, the  
8 pooled rate of digestive symptoms was 15% (95% CI: 10%- 21%; range: 2%–57%;  $I^2=$   
9 96%; **supplementary Figure 3**). Specifically, nausea and/or vomiting, diarrhoea and  
10 anorexia were the main GI symptoms. The pooled estimate rate of diarrhoea was 9%  
11 (95% CI: 6%- 12%; range: 1%– 34%;  $I^2=89\%$ ; 26 studies(n=), **Figure 2a**).The pooled  
12 estimate of nausea and/or vomiting rates were 7% (95% CI: 5%- 9%; range: 1%–22%;  
13  $I^2=88\%$ ; 18 studies(n=)), loss of appetite was 21% (95% CI: 9%–44%; range: 1%– 79%;  
14  $I^2=98\%$ ; 8 studies (n=), and abdominal pain was 3% (95% CI: 2%–5%; range: 1%– 4%;  
15  $I^2=31\%$ ; 6 studies(n=)), respectively (**Figure 2b-d**).

16

### 17 **3.4 Liver injury**

18 Regarding presence of liver injury, the pooled estimate of 12 studies (n=1,267) was 19%  
19 (95% CI: 9%-32%; range: 1%-53%;  $I^2=96\%$ ; **supplementary Figure 4**). More  
20 specifically, the pooled estimate of the rate of elevated ALT was 18% (95% CI: 13%–  
21 25%; range: 4%–40%;  $I^2=90\%$ ), elevated AST was 21% (95% CI: 14%–29%; range:

1 4%–53%;  $I^2=92\%$ ), and elevated TB was 8% (95% CI: 3%–18%; range: 1%–31%;  $I^2=$   
2 94%; **Figure 3a-c**). The pooled estimate of the rate of decreased ALB (albumin) was  
3 32% (95% CI: 3%–89%; range: 6%–78%;  $I^2=98\%$ ; **Figure 3d**).

4

### 5 ***3.5 The clinical course of patients with GI symptoms***

6 The proportion of severe/critical cases was markedly increased in COVID-19 patients  
7 with GI symptoms compared with those without GI symptoms (31.6% vs.13.4%, OR  
8 3.97, 95% CI: 1.49-10.62,  $p=0.0060$ ,  $I^2=79\%$ , **Figure 4**). However, the risk of severe  
9 disease was not increased among patients with digestive/liver-related comorbidities  
10 (OR 0.57, 95% CI:0.15, 2.18,  $p=0.41$ ,  $I^2=44\%$ ) when compared with patients without  
11 these comorbidities (supp. **Figure 5**).

12 Patients with GI symptoms had a higher risk of ARDS (OR 2.96, 95% CI: 1.17- 7.48,  
13  $p=0.020$ ) and liver injury (OR 2.71, 95% CI: 1.52-4.83,  $p<0.01$ ) (supp. **Figure 6**).

14 However, the pooled rate of discharge (OR 0.72, 95% CI: 0.37-1.41,  $p=0.34$ ,  $n=458$ ,

15 **Figure 4**), the length of hospital stay (SMD 1.70, 95% CI: -0.81, 4.21,  $P=0.18$ ,  $n=341$ )

16 and the rates of death (OR 1.21, 95% CI: 0.68-2.16,  $p=0.52$ ,  $I^2=8\%$ , **Figure 4**) were

17 comparable between patients with and without GI symptoms.

18

## 19 **4. Subgroup analysis**

### 20 ***4.1 Severe Vs non-severe COVID-19***

1 We analysed the difference in GI symptoms between severe and non-severe patients  
2 with COVID-19 (Figure 5). Patients with severe cases were more likely to present with  
3 GI symptoms compared to non-severe ones (OR 1.61, 95% CI: 1.09, 2.36,  $p=0.020$ ,  
4  $I^2=44\%$ ). More specifically, a higher risk of patients presenting with abdominal pain  
5 (OR 7.15, 95% CI: 1.95, 26.27;  $p=0.0030$ ,  $I^2=0$ ) was observed in the severe group  
6 compared to those in non-severe patients. However, there were no statistically  
7 significant difference between severe and non-severe patients in loss of appetite (OR  
8 2.83, 95% CI: 0.92, 8.69,  $p=0.070$ ,  $I^2=64\%$ ), diarrhoea (OR 1.22, 95% CI: 0.81-1.84;  
9  $p=0.35$ ,  $I^2=0$ ) , or nausea and/or vomiting (OR 1.23, 95% CI: 0.69-2.19;  $p=0.49$ ,  
10  $I^2=32\%$ ).

11 A higher risk of liver injury was observed in the severe group compared to those in non-  
12 severe group with an OR of 2.2 (95% CI: 1.60-3.02,  $p<0.001$ ,  $I^2=36\%$ , **Figure 6**). The  
13 value of liver damage indices such as ALT (standardized mean difference(SMD), 0.46;  
14 95% CI, 0.27 to 0.65;  $P < 0.001$ ) and AST (SMD, 0.36; 95% CI, 0.12 to 0.60;  $P =$   
15  $0.0030$ ) and TB (SMD, 0.28; 95% CI, 0.02 to 0.54;  $P = 0.030$ ) levels were significantly  
16 elevated in patients with severe group compared with non-severe group  
17 (**Supplementary. Figure 7**). However, the pooled analysis failed to demonstrate a  
18 significant difference in albumin (ALB) levels between two groups (SMD,- 0.23; 95%  
19 CI, -0.51 to 0.06;  $P =0.11$ ; **Supplementary. Figure 7**).

## 21 4.2 Patients in Hubei vs. outside Hubei

1 We further analysed the differences between patients in Hubei (the place of COVID-19  
2 initial outbreak in China, n=4,009) vs. outside Hubei province (n=2,677). The incidence  
3 of overall GI symptoms at diagnosis (17% [95%CI 10-28%] vs. 9% [95%CI 6-14%]; p=  
4 0.078) were comparable between the two groups. There was a higher proportion of  
5 patients in Hubei presenting with nausea and/or vomiting (8% [95%CI 5-11%] vs.  
6 4% [95%CI 3-7%]; P=0.045) compared to those outside Hubei (**Appendix,**  
7 **Supplementary Table 5**). Other symptoms including diarrhoea and loss of appetite  
8 were comparable between patients in Hubei and outside Hubei.  
9 However, there is a higher risk of liver injury in patients of Hubei compared to those  
10 outside Hubei (21% [95%CI 4-59%] vs. 10% [95%CI 4-25%]; P<0.01). This trend is  
11 further confirmed by the data that a larger proportion of patients in Hubei had elevated  
12 ALT (25% [95%CI 17-35%] vs. 15% [95%CI 9-23%]; P=0.069), AST (30% [95%CI  
13 18-46%] vs. 16% [95%CI 11-24%]; P=0.053) and TB (24% [95%CI 16-33%] vs. 4%  
14 [95%CI 2-9%]; P<0.001) compared to cases outside Hubei (**Appendix,**  
15 **Supplementary Table 5**).

16

### 17 **4.3 Adult vs Paediatric patients**

18 We further analysed whether digestive symptoms varied between adult (n=6420) and  
19 paediatric patients (n=266). GI symptoms including diarrhoea (9% [95%CI 6-13%] vs.  
20 10% [95%CI 6-15%], p=0.78), and nausea and/or vomiting (7% [95%CI 5-9%] vs. 6%  
21 [95%CI 4-11%]; P=0.95) were comparable between the two groups (**Appendix,**

1 **Supplementary Table 5).** Similarly, paediatric patients with COVID-19 had an  
2 equivalent risk of liver injury (10% [95%CI 4-22%] vs. 18% [95%CI 8-35%]; P= 0.32),  
3 as compared with adult cases. However, paediatric patients were less likely to present  
4 with elevated ALT compared with adult patients (7% [95%CI 3-18%]; P=0.034 vs. 20%  
5 [95%CI 14-28%] ) (**Appendix, Supplementary Table 5**).

6

## 7 **5. Publication bias**

8 Significant publication bias was found either by funnel plot or by the Egger test (p  
9 <0.01) for GI symptoms (**supplementary. Figure 8**) but not for liver injury (p= 0.18).

10

11

## 1 **Discussion**

2 An increasing number of studies reported the involvement of the digestive system in  
3 patients with COVID-19. The present study aimed to investigate the pooled rate of GI  
4 symptoms and liver injury in COVID-19. Overall, the pooled rates of GI symptom and  
5 liver injury were 15% and 19% in patients with COVID-19, respectively. As the  
6 severity of the disease increases, digestive symptoms and liver injury become more  
7 pronounced. About 10% patients presented with GI symptoms alone without  
8 respiratory features. Patients with GI system involvement tend to have delayed  
9 diagnosis, higher risk of severe/critical disease and development of ARDS.

10

11 Over the course of the current pandemic, some patients can initially present with  
12 abdominal symptoms even without fever or respiratory manifestations<sup>58</sup>. In a large  
13 multicentre study,<sup>12</sup> of 204 patients with COVID-19 in three heavily affected hospitals  
14 during the initial outbreak in China, 99 patients (48.5%) presented with digestive  
15 symptoms as their chief complaint. There were 7 cases presenting with digestive  
16 symptoms but no respiratory symptoms. Luo<sup>40</sup> reported a large case series (n=1,141) of  
17 hospitalised patients with SARS-CoV-2 infection, 183 (16%) presented with  
18 gastrointestinal symptoms only. Wang et al<sup>33</sup> also found around one in ten (10.1%)  
19 patients initially presented with diarrhoea and nausea 1 to 2 days prior to development  
20 of fever and dyspnoea. In the present study, about 10% (95% CI: 4%- 19%; range: 3%–  
21 23%;  $I^2=97%$ ) patients presented with GI symptoms alone without respiratory features.

1

2 Patients with digestive symptoms had a variety of manifestations, such as loss of  
3 appetite (83 (83.8%) cases), diarrhoea (29 (29.3%) cases), vomiting (8 (0.8%) cases),  
4 and abdominal pain (4 (0.4%) cases).<sup>12</sup> According to the present study, 15% (95% CI:  
5 10%- 21%) patients with COVID-19 presented with digestive symptoms, including  
6 nausea and/or vomiting with a pooled rate of 7% (95% CI: 5%- 9%), diarrhoea 9% (95%  
7 CI: 6–12%), loss of appetite 21% (95% CI: 9–44%), and abdominal pain 4% (95% CI:  
8 3–4%). Autopsy studies are important to help investigate the histopathological change  
9 of GI tract in COVID-19. Currently there is only one published autopsy report in an 85-  
10 year-old man with COVID-19, which showed segmental dilatation and stenosis in the  
11 small intestine.<sup>64</sup> Further studies are needed to clarify whether this finding is secondary  
12 to COVID-19 or a pre-existing GI comorbidity.

13 In addition to digestive symptoms, patients with COVID-19 are also at risk of  
14 developing liver injury. Recent studies have shown that patients had varying degrees of  
15 liver function abnormalities, the incidence ranged from 14.8% to 53%, mainly indicated  
16 by abnormal ALT and AST levels, accompanied by slightly elevated bilirubin levels.  
17 The albumin was decreased in severe cases and the level of albumin was around 26.3-  
18 30.9 g/L.<sup>32</sup> In our study, the pooled estimate of liver injury was 19% (95% CI: 9%-  
19 32%). Our findings indicate that one in five patients will develop liver function  
20 abnormalities, especially in severe cases (may be as high as 53%), thus special notice

1 of liver dysfunction should be taken in treating COVID-19 patients over the  
2 hospitalisation period.

3 The characteristics of the liver injury was slight elevation in hepatocyte related enzymes  
4 including ALT and AST. Cholangiocyte related enzymes such as alkaline  
5 phosphatase (ALP) and  $\gamma$ -glutamyl transpeptidase (GGT) were also reported to be  
6 slightly elevated in a few patients (3.1% and 3.0%).<sup>65</sup> Studies on the exact mechanism  
7 of COVID-19 related liver injury are scarce. Liver abnormalities of COVID-19 patients  
8 may be due to viral infection in liver cells or other causes such as drug toxicity and  
9 systemic inflammation <sup>66</sup>. A recent postmortem biopsy study in a COVID-19 patient  
10 showed moderate microvascular steatosis and mild lobular and portal activity,  
11 indicating the injury could have been caused by either COVID-19 infection or drug-  
12 induced liver injury.<sup>67 68</sup> Similar to the situation in SARS, drugs such as antivirals might  
13 potentially cause liver injury in COVID-19. <sup>69</sup> However, one study reported that there  
14 was no statistical difference between patients on medication or not when stratified by  
15 the prehospital medications including antibacterial drugs, antiviral drugs (abidol,  
16 oseltamivir, acyclovir), and antipyretic drugs with paracetamol (acetaminophen).<sup>68</sup>  
17 Further studies are warranted in this setting.

18 The link between GI involvement and disease severity of COVID-19 has been proposed  
19 recently. In a multicentre study, Lei et al. <sup>12</sup>investigated the prevalence and outcomes  
20 of COVID-19 patients with digestive symptoms. In 99 patients who presented with  
21 digestive symptoms as chief complaint, a longer time from onset to admission was



1 observed compared to patients without digestive symptoms (9.0 days vs. 7.3 days). As  
2 the severity of the disease increased, digestive symptoms became more pronounced.  
3 Patients without digestive symptoms were more likely to be cured and discharged than  
4 patients with digestive symptoms (60% vs. 34.3%).<sup>12</sup> This was consistent with the study  
5 from Wang et al who found that patients admitted to the ICU were more likely to have  
6 abdominal pain and loss of appetite compared with the non-ICU patients.<sup>33</sup> In the  
7 present study, we performed subgroup analysis to investigate the difference in GI  
8 symptoms between severe and non-severe patients with COVID-19. Indeed, there was  
9 a higher prevalence of GI symptoms (OR 1.61, 95% CI: 1.09-2.36, p=0.020), including  
10 anorexia (OR 2.83, 95% CI: 0.92-8.691, p=0.070), and abdominal pain (OR 7.15, 95%  
11 CI: 1.95-26.27; p=0.0030) in the severe group compared to the non-severe cases. Cai  
12 et al<sup>65</sup> showed liver injury occurred more frequently in severe patients (36.2% vs. 9.6%,  
13 p<0.001) than non-severe patients. We also found a significantly higher risk of liver  
14 function abnormalities in the severe group compared to those in non-severe group(OR  
15 2.2, 95% CI: 1.60-3.02, p<0.001). In COVID-19 cases who died, the incidence of liver  
16 injury might reach as high as 58.06%<sup>70</sup> and 78%<sup>71</sup>. One study reported that serum ALT  
17 and AST levels increased up to 7590 U/L and 1445 U/L respectively in a severe  
18 COVID-19 patient.<sup>32</sup>

19 In the present study, we further investigated the disease course and outcomes in  
20 subgroups of patients with digestive system involvement. We found patients presenting  
21 with initial GI symptoms had longer duration from illness onset to admission (SMD

1 2.85, 95% CI: 0.22-5.48,  $p=0.030$ ), and the rate of the severe/critical type was markedly  
2 increased when compared to those without GI symptoms (31.6% vs.13.4%, OR 3.97,  
3 95% CI: 1.49-10.62,  $p=0.0060$ ). Patients with GI symptoms also had a higher risk of  
4 ARDS (OR 2.96, 95% CI: 1.17- 7.48,  $p=0.020$ ). No significant difference was seen  
5 when considering pooled rates of discharge (OR 0.72, 95% CI: 0.37-1.41,  $p=0.34$ ),  
6 length of hospital stay (SMD 1.70, 95% CI: -0.81, 4.21,  $P=0.18$ ) and rates of death (OR  
7 1.21, 95% CI: 0.68-2.16,  $p =0.52$ ) between patients with and without GI symptoms.  
8 This may be due to the relatively low incidence of each event. Moreover, the risk of  
9 severe case was not increased among COVID-19 patients with existing digestive/liver-  
10 related comorbidity when compared with patients without such comorbidity (OR 0.57,  
11 95% CI:0.15, 2.18,  $p=0.41$ ). Thus, the newly presenting GI symptoms rather the  
12 existing digestive/liver-related comorbidity were predictive of severe disease course.  
13 Altogether, our findings supported the importance of including symptoms like  
14 diarrhoea to diagnose COVID-19 early.

15

16 The characteristics of patients with imported COVID-19 outside Hubei may vary from  
17 patients in Hubei. An early study including 80 imported cases of COVID-19 in Jiangsu  
18 Province showed that imported cases exhibited mild or moderate symptoms and lower  
19 proportion of liver dysfunction compared with the cases in Wuhan.<sup>38</sup> Our subgroup  
20 analysis suggested that there was no difference in rate of overall GI symptoms. Patients  
21 in Hubei had a higher risk of presenting with abnormal liver function. It might be argued

1 that there were more severe cases in Hubei compared with those outside Hubei, which  
2 may result in the higher percentage of patients with abnormal liver function in Hubei.  
3 However, our present analysis included studies that did not show significant difference  
4 in percentage of severe cases between Hubei and outside Hubei (data not shown). This  
5 needs to be further investigated in future studies.

6

7 A few paediatric cases are reported and their clinical features have yet to be fully  
8 evaluated. In a recent landmark clinical investigation on ten paediatric COVID-19 cases  
9 in China, these patients had clinically milder symptoms and showed fewer alterations  
10 in radiological and laboratory testing parameters.<sup>8</sup> In the present study, we included 4  
11 paediatric studies with 227 patients in total.<sup>8, 37, 43, 54</sup> According to our subgroup analysis,  
12 paediatric patients with COVID-19 had a lower risk of elevated ALT, as compared with  
13 adult cases. However, the GI symptoms including diarrhoea, and nausea or vomiting  
14 were comparable between paediatric and adult patients.

15

16 Emerging data showed the prolonged presence of COVID-19 virus RNA in stool  
17 samples or rectal swab even after the patients' respiratory specimens were negative.<sup>8, 61</sup>  
18 Much attention has been paid to the possibility of virus shedding by gastrointestinal tract  
19 and faecal–oral transmission. In the clinical investigation on ten paediatric COVID-19  
20 cases, eight persistently tested positive on rectal swabs even after nasopharyngeal testing  
21 was negative.<sup>8</sup> After reviewing all studies testing virus RNA in stool or rectal swabs,

1 the positive rate of COVID-19 viral RNA in faecal samples was 54% (95%CI 44%-  
2 64%), the duration of virus positivity can persist for as long as 47 days after symptom  
3 onset (**Appendix, supplementary Table 3**). Data from Wu et al <sup>61</sup> suggest the possibility  
4 of extended duration of viral shedding in faeces, for nearly 5 weeks after the patients'  
5 respiratory samples tested negative for COVID-19. However, the clinical implication of  
6 prolonged faecal virus excretion including its association with disease course, severity  
7 and even recurrence of COVID-19 remains unclarified. It clearly may have major public  
8 health and clinical policy significance. More studies are needed to demonstrate its  
9 replication-competence, its abundance in stool and stability in environment<sup>72-73</sup>.

10

11 This meta-analysis is potentially limited in several ways. First, an assessment of the  
12 methodological quality determined that there were deficiencies in studies evaluated, as  
13 all the 35 studies included were considered low-quality. Second, due to lack of  
14 sufficient data reported in the original publications, it was not possible to evaluate the  
15 effect of other factors, such as gender, age, and comorbidities, on the rate of  
16 gastrointestinal symptoms at diagnosis, and risk of liver injury. Third, the criteria for  
17 severe COVID-19 differed among studies, which may contribute to the heterogeneity  
18 of the meta-analysis. As defined in the methods section, we took the criteria per study,  
19 in other cases we defined the severe cases by their symptoms (SpO2<90% or ARDS)  
20 or poor prognosis (need of ICU care). Last but not the least, significant heterogeneity  
21 and publication bias were observed in our study for estimating the prevalence of

1 digestive system symptoms. After reviewing each study, the majority of heterogeneity  
2 were from nonspecific symptom of appetite loss, and two studies <sup>40, 49</sup> focusing on  
3 patients with GI symptoms. When these studies were excluded from the analysis, the  
4 pooled rate of digestive symptoms was 7% (95% CI: 5%- 8%;  $I^2= 78\%$ ), which is of  
5 modest heterogeneity. The pooled rate is lower than 15% due to the high incidence of  
6 loss of appetite. However, the pooled rates of other three symptoms were similar to  
7 original results with only mild or modest heterogeneity.

8 In conclusion, the present systematic review and meta-analysis suggest that the  
9 digestive symptoms and liver injury are not uncommon in patients with COVID-19.  
10 Compared with non-severe cases, severe cases with COVID-19 had a higher risk of  
11 developing GI symptoms and liver injury. Patients in Hubei had comparable risk of  
12 developing GI symptoms but higher risk of liver injury than those outside Hubei.  
13 Paediatric patients with COVID-19 have equivalent risk of GI symptoms compared  
14 with adult patients. One tenth of patients with COVID-19 may present only with GI  
15 symptoms without respiratory symptoms. Patients with GI system involvement have  
16 delayed diagnosis with a tendency to severe/critical type and a poor disease course.  
17 More attention should be paid to the care of these unique group of patients.

18 ***References***

19 1. Coronavirus disease 2019 (COVID-19) Situation Report – 74.  
20 [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200403-sitrep-](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200403-sitrep-74-covid-19-mp.pdf?sfvrsn=4e043d03_14)  
21 [74-covid-19-mp.pdf?sfvrsn=4e043d03\\_14](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200403-sitrep-74-covid-19-mp.pdf?sfvrsn=4e043d03_14). Accessed April 12, 2020.

1 2. WJ Guan, Z Ni, Y Hu, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl*  
2 *J Med* 2020. DOI: 10.1056/NEJMoa2002032

3 3. F Xiao, M Tang, X Zheng, et al. Evidence for gastrointestinal infection of SARS-CoV-2.  
4 *Gastroenterology* 2020. DOI: 10.1053/j.gastro.2020.02.055.

5 4. F Qi, S Qian, S Zhang, et al. Single cell RNA sequencing of 13 human tissues identify cell types  
6 and receptors of human coronaviruses. *Biochemical and biophysical research communications*  
7 2020. DOI: 10.1016/j.bbrc.2020.03.044.

8 5. ML Holshue, C DeBolt, S Lindquist, et al. First Case of 2019 Novel Coronavirus in the United  
9 States. *New England Journal of Medicine* 2020;382:929-936. DOI: 10.1056/NEJMoa2001191

10 6. R Wölfel, VM Corman, W Guggemos, et al. Virological assessment of hospitalized patients with  
11 COVID-2019. *Nature* 2020. DOI: 10.1038/s41586-020-2196-x

12 7. X Yao, T Li, Z He, et al. A pathological report of three COVID-19 cases by minimally invasive  
13 autopsies. *Chinese journal of pathology* 2020;49:E009. DOI: 10.3760/cmaj.cn112151-  
14 20200312-00193

15 8. Y Xu, X Li, B Zhu, et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence  
16 for persistent fecal viral shedding. *Nature Medicine* 2020. DOI: 10.1038/s41591-020-0817-4

17 9. D Chang M Lin, L Wei, et al. Epidemiologic and Clinical Characteristics of Novel Coronavirus  
18 Infections Involving 13 Patients Outside Wuhan, China. *JAMA* 2020. DOI:  
19 10.1001/jama.2020.1623

20 10. L Wang, Y Gao, L Lou, et al. The clinical dynamics of 18 cases of COVID-19 outside of Wuhan,  
21 China. *The European respiratory journal* 2020. DOI: 10.1183/13993003.00398-2020

- 1 11. X Jin, J Lian, J Hu, et al. Epidemiological, clinical and virological characteristics of 74 cases of  
2 coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut 2020. DOI:  
3 10.1136/gutjnl-2020-320926
- 4 12. L Pan M Mu, H Ren, et al.. Clinical characteristics of COVID-19 patients with digestive  
5 symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study American journal  
6 of gastroenterology 2020. DOI: 10.14309/ajg.0000000000000620
- 7 13. National Heart, Lung, and Blood Institute website. Study quality assessment tools.  
8 [www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools](http://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools). Accessed February 16,  
9 2020
- 10 14. Z Wang, B Yang, Q Li, et al. Clinical Features of 69 Cases with Coronavirus Disease 2019 in  
11 Wuhan, China. Clinical infectious diseases : an official publication of the Infectious Diseases  
12 Society of America 2020. DOI: 10.1093/cid/ciaa272
- 13 15. C Huang, Y Wang, X Li, et al. Clinical features of patients infected with 2019 novel coronavirus  
14 in Wuhan, China. Lancet (London, England) 2020;395:497-506. DOI: 10.1016/S0140-  
15 6736(20)30183-5
- 16 16. C Wu, X Chen, Y Cai, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome  
17 and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA  
18 internal medicine 2020. DOI: 10.1001/jamainternmed.2020.0994
- 19 17. Coronavirus disease (COVID-19) technical guidance: Laboratory testing for 2019-nCoV in  
20 humans. [https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance)  
21 [guidance/laboratory-guidance](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance). Accessed April 12, 2020.

- 1 18. SP Hozo, B Djulbegovic, I Hozo. Estimating the mean and variance from the median, range, and  
2 the size of a sample. BMC medical research methodology 2005;5:13. DOI: 10.1186/1471-2288-  
3 5-13
- 4 19. M Egger, G Smith, M Schneider, et al. Bias in meta-analysis detected by a simple, graphical test.  
5 BMJ (Clinical research ed.) 1997;315:629-34. DOI: 10.1136/bmj.315.7109.629
- 6 20. Q Li, X Guan, P Wu, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–  
7 Infected Pneumonia. New England Journal of Medicine 2020;382:1199-1207. DOI:  
8 10.1056/NEJMoa2001316
- 9 21. Y Pan, D Zhang, P Yang, et al. Viral load of SARS-CoV-2 in clinical samples. The Lancet. Infectious  
10 diseases 2020;20:411-412. DOI: 10.1016/S1473-3099(20)30113-4
- 11 22. Q Chen, B Quan, X Li, et al. A report of clinical diagnosis and treatment of nine cases of  
12 coronavirus disease 2019. Journal of Medical Virology 2020. DOI: 10.1002/jmv.25755
- 13 23. JF Chan, S Yuan, K Kok, et al. A familial cluster of pneumonia associated with the 2019 novel  
14 coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet  
15 (London, England) 2020;395:514-523. DOI: 10.1016/S0140-6736(20)30154-9
- 16 24. Z Wang, X Chen, Y Lu, et al. Clinical characteristics and therapeutic procedure for four cases  
17 with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine  
18 treatment. Bioscience trends 2020;14:64-68. DOI: 10.5582/bst.2020.01030
- 19 25. Z Zhang, X Li, W Zhang, et al. Clinical Features and Treatment of 2019-nCov Pneumonia  
20 Patients in Wuhan: Report of A Couple Cases. Virologica Sinica 2020. DOI: 10.1007/s12250-  
21 020-00203-8



- 1 26. F Lescure, L Bouadma, D Nguyen, et al. Clinical and virological data of the first cases of COVID-  
2 19 in Europe: a case series. *The Lancet. Infectious diseases* 2020. DOI: 10.1016/S1473-  
3 3099(20)30200-0
- 4 27. C Luo, L Yao, L Zhang, et al. Possible Transmission of Severe Acute Respiratory Syndrome  
5 Coronavirus 2 (SARS-CoV-2) in a Public Bath Center in Huai'an, Jiangsu Province, China. *JAMA*  
6 *network open* 2020;3:e204583. DOI: 10.1001/jamanetworkopen.2020.4583
- 7 28. N Yu, W Li, Q Kang, et al. Clinical features and obstetric and neonatal outcomes of pregnant  
8 patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study. *The*  
9 *Lancet. Infectious diseases* 2020. DOI: 10.1016/S1473-3099(20)30176-6
- 10 29. L Zeng, S Xia, W Yuan, et al. Neonatal Early-Onset Infection With SARS-CoV-2 in 33 Neonates  
11 Born to Mothers With COVID-19 in Wuhan, China. *JAMA pediatrics* 2020. DOI:  
12 10.1001/jamapediatrics.2020.0878
- 13 30. M Arentz, E Yim, L Klaff, et al. Characteristics and Outcomes of 21 Critically Ill Patients With  
14 COVID-19 in Washington State. *JAMA* 2020. DOI: 10.1001/jama.2020.4326
- 15 31. BE Young, S Ong, S Kalimuddin, et al. Epidemiologic Features and Clinical Course of Patients  
16 Infected With SARS-CoV-2 in Singapore. *JAMA* 2020. DOI: 10.1001/jama.2020.3204
- 17 32. N Chen, M Zhou, X Dong, et al. Epidemiological and clinical characteristics of 99 cases of 2019  
18 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *The Lancet* 2020;395:507-  
19 513. DOI: 10.1016/S0140-6736(20)30211-7
- 20 33. D Wang, B Hu, C Hu, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel  
21 Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* 2020. DOI: 10.1001/jama.2020.1585

- 1 34. F Song, N Shi, F Shan, et al. Emerging 2019 Novel Coronavirus (2019-nCoV) Pneumonia.  
2 Radiology 2020;295:210-217. DOI: 10.1148/radiol.2020200274
- 3 35. F Zhou, T Yu, R Du, et al. Clinical course and risk factors for mortality of adult inpatients with  
4 COVID-19 in Wuhan, China: a retrospective cohort study. Lancet (London, England) 2020. DOI:  
5 10.1016/S0140-6736(20)30566-3
- 6 36. H Shi, X Han, N Jiang, et al. Radiological findings from 81 patients with COVID-19 pneumonia  
7 in Wuhan, China: a descriptive study. The Lancet. Infectious diseases 2020. DOI:  
8 10.1016/S1473-3099(20)30086-4
- 9 37. J Cai, J Xu, D Lin, et al. A Case Series of children with 2019 novel coronavirus infection: clinical  
10 and epidemiological features. Clinical infectious diseases : an official publication of the  
11 Infectious Diseases Society of America 2020. DOI: 10.1093/cid/ciaa198
- 12 38. J Wu, J Liu, X Zhao, et al. Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu  
13 Province: A Multicenter Descriptive Study. Clinical infectious diseases : an official publication  
14 of the Infectious Diseases Society of America 2020. DOI: 10.1093/cid/ciaa199
- 15 39. K Liu, Y Fang, Y Deng, et al. Clinical characteristics of novel coronavirus cases in tertiary  
16 hospitals in Hubei Province. Chinese medical journal 2020. DOI:  
17 10.1097/CM9.0000000000000744
- 18 40. S Luo, X Zhang, H Xu. Don't overlook digestive symptoms in patients with 2019 novel  
19 coronavirus disease (COVID-19). Clinical Gastroenterology and Hepatology 2020. DOI:  
20 10.1016/j.cgh.2020.03.043

- 1 41. M Ng, E Lee, J Yang, et al. Imaging Profile of the COVID-19 Infection: Radiologic Findings and  
2 Literature Review. *Radiology: Cardiothoracic Imaging* 2020;2:e200034. DOI:  
3 10.1148/ryct.2020200034
- 4 42. W Yang, Q Cao, L Qin, et al. Clinical characteristics and imaging manifestations of the 2019  
5 novel coronavirus disease (COVID-19): A multi-center study in Wenzhou city, Zhejiang, China.  
6 *The Journal of infection* 2020. DOI: 10.1016/j.jinf.2020.02.016
- 7 43. X Lu, L Zhang, H Du, et al. SARS-CoV-2 Infection in Children. *The New England journal of*  
8 *medicine* 2020. DOI: 10.1056/NEJMc2005073
- 9 44. X Xu, C Yu, J Qu, et al. Imaging and clinical features of patients with 2019 novel coronavirus  
10 SARS-CoV-2. *European journal of nuclear medicine and molecular imaging* 2020. DOI:  
11 10.1007/s00259-020-04735-9
- 12 45. X Xu, X Wu, X Jiang, et al. Clinical findings in a group of patients infected with the 2019 novel  
13 coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. *BMJ*  
14 2020;368:m606. DOI: 10.1136/bmj.m606
- 15 46. Y Liu, Y Yang, C Zhang, et al. Clinical and biochemical indexes from 2019-nCoV infected patients  
16 linked to viral loads and lung injury. *Science China. Life sciences* 2020;63:364-374. DOI:  
17 10.1007/s11427-020-1643-8
- 18 47. Z Zhou, N Zhao, Y Shu, et al. Effect of gastrointestinal symptoms on patients infected with  
19 COVID-19. *Gastroenterology* 2020. DOI: 10.1053/j.gastro.2020.03.020
- 20 48. J Zhang, X Dong, Y Cao, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2  
21 in Wuhan, China. *Allergy* 2020. DOI: 10.1111/all.14238

- 1 49. C Han, C Duan, S Zhang, et al. Digestive Symptoms in COVID-19 Patients with Mild Disease  
2 Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes American journal of  
3 gastroenterology 2020.
- 4 50. B Cao, Y Wang, D Wen, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe  
5 Covid-19. The New England journal of medicine 2020. DOI: 10.1056/NEJMoa2001282
- 6 51. W Guo, M Li, Y Dong, et al. Diabetes is a risk factor for the progression and prognosis of COVID-  
7 19. Diabetes/metabolism research and reviews 2020:e3319. DOI: 10.1002/dmrr.3319
- 8 52. X Jin, J Lian, J Hu, et al. Epidemiological, clinical and virological characteristics of 74 cases of  
9 coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut 2020. DOI:  
10 10.1136/gutjnl-2020-320926
- 11 53. M Du, G Cai, F Chen, et al. Multi-omics Evaluation of Gastrointestinal and Other Clinical  
12 Characteristics of SARS-CoV-2 and COVID-19. Gastroenterology 2020.
- 13 54. H Qiu, J Wu, L Hong, et al. Clinical and epidemiological features of 36 children with coronavirus  
14 disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. The Lancet.  
15 Infectious diseases 2020. DOI: 10.1016/S1473-3099(20)30198-5
- 16 55. S Shi, M Qin, B Shen, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients  
17 With COVID-19 in Wuhan, China. JAMA cardiology 2020. DOI: 10.1001/jamacardio.2020.0950
- 18 56. P Wu, F Duan, C Luo, et al. Characteristics of Ocular Findings of Patients With Coronavirus  
19 Disease 2019 (COVID-19) in Hubei Province, China. JAMA ophthalmology 2020. DOI:  
20 10.1001/jamaophthalmol.2020.1291

- 1 57. M Zheng, Y Gao, G Wang, et al. Functional exhaustion of antiviral lymphocytes in COVID-19  
2 patients. *Cellular & molecular immunology* 2020. DOI: 10.1038/s41423-020-0402-2
- 3 58. Y Song, P Liu, X Shi, et al. SARS-CoV-2 induced diarrhoea as onset symptom in patient with  
4 COVID-19. *Gut* 2020. DOI: 10.1136/gutjnl-2020-320891
- 5 59. FF Guglielmo, SA Anupindi, JG Fletcher, et al. Small Bowel Crohn Disease at CT and MR  
6 Enterography: Imaging Atlas and Glossary of Terms. *Radiographics* 2020:190091. DOI:  
7 10.1148/rg.2020190091
- 8 60. I Ghinai, TD McPherson, JC Hunter, et al. First known person-to-person transmission of severe  
9 acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA. *The Lancet*. DOI:  
10 10.1016/S0140-6736(20)30607-3
- 11 61. Y Wu, C Guo, L Tang, et al. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. *The*  
12 *lancet*. *Gastroenterology & hepatology* 2020. DOI: 10.1016/S2468-1253(20)30083-2
- 13 62. A Carvalho, R Alqusairi, A Adams, et al. SARS-CoV-2 Gastrointestinal Infection Causing  
14 Hemorrhagic Colitis: Implications for Detection and Transmission of COVID-19 Disease.  
15 *American journal of gastroenterology* 2020.
- 16 63. C Chen, G Gao, Y Xu, et al. SARS-CoV-2-Positive Sputum and Feces After Conversion of  
17 Pharyngeal Samples in Patients With COVID-19. *Annals of internal medicine* 2020. DOI:  
18 10.7326/M20-0991
- 19 64. T Hosoda, M Sakamoto, H Shimizu, et al. SARS-CoV-2 enterocolitis with persisting to excrete  
20 the virus for about two weeks after recovering from diarrhea: A case report. *Infection control*  
21 *and hospital epidemiology* 2020:1-4. DOI: 10.1017/ice.2020.87

- 1 65. Q Liu, R Wang, G Qu, et al. Macroscopic autopsy findings in a patient with COVID-19. Journal  
2 of Forensic Medicine (in Chinese) 2020;36:1-3.
- 3 66. Q Cai, D Huang, P Ou, et al. COVID-19 in a Designated Infectious Diseases Hospital Outside  
4 Hubei Province, China. medRxiv 2020. DOI: 10.1101/2020.02.17.20024018
- 5 67. X Chai, L Hu, Y Zhang, et al. Specific ACE2 Expression in Cholangiocytes May Cause Liver  
6 Damage After 2019-nCoV Infection. bioRxiv 2020. DOI: 10.1101/2020.02.03.931766
- 7 68. Z Xu, L Shi, Y Wang, et al. Pathological findings of COVID-19 associated with acute respiratory  
8 distress syndrome. The Lancet. Respiratory medicine 2020. DOI: 10.1016/S2213-  
9 2600(20)30076-X
- 10 69. Z Fan, L Chen, J Li, et al. Clinical Features of COVID-19 Related Liver Damage. medRxiv 2020.  
11 DOI: 10.1101/2020.02.26.20026971
- 12 70. X Yang, Y Yu, J Xu, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2  
13 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet.  
14 Respiratory medicine 2020. DOI: 10.1016/S2213-2600(20)30079-5
- 15 71. Y Huang, R Yang, Y Xu, et al. Clinical characteristics of 36 non-survivors with COVID-19 in  
16 Wuhan, China. medRxiv 2020. DOI: 10.1101/2020.02.27.20029009
- 17 72. B Zhang, X Zhou, Y Qiu, et al. Clinical characteristics of 82 death cases with COVID-19. medRxiv  
18 2020. DOI: 10.1101/2020.02.26.20028191
- 19 73. N van Doremalen, T Bushmaker, DH Morris, et al. Aerosol and Surface Stability of SARS-CoV-2  
20 as Compared with SARS-CoV-1. The New England journal of medicine 2020. DOI:  
21 10.1056/NEJMc2004973

- 1 74. C Yeo, S Kaushal, D Yeo. Enteric involvement of coronaviruses: is faecal-oral transmission of  
2 SARS-CoV-2 possible? *The lancet. Gastroenterology & hepatology* 2020;5:335-337. DOI:  
3 10.1016/S2468-1253(20)30048-0

## **Figure Legends**

**Figure 1.** Study selection

**Figure 2.** Pooled estimate of GI symptoms spectrum: (a) nausea and/or vomiting, (b) diarrhoea, (c) loss of appetite and (d) abdominal pain in patients with COVID-19.

**Figure 3.** Estimated incidence of abnormal liver chemistry including (a) elevated ALT, (b) elevated AST, (c) elevated TB, and (d) decreased ALB in patients with COVID-19.

**Figure 4.** Prognosis of patients with COVID-19: Estimated incidence of (a) severe case, (b) discharge and (c) mortality, stratified by digestive system involvement

**Figure 5.** Forrest plot of meta-analysis of GI symptoms according to patients' disease severity (severe vs. non-severe).

**Figure 6.** Forrest plot of meta-analysis of odds ratio of liver chemistry according to patients' disease severity (severe vs. non-severe).